Recon: EU looks to pay less than $40 per COVID-19 vaccine; Taro to pay upwards of $200M to settle price-fixing suit

• Trump will sign executive orders on lowering drug prices on Friday: White House (Reuters)
• Trump drops plan to eliminate government drug rebates (Politico)
• US Clears Way for Drugmakers to Share COVID Antibody Capacity (Reuters)
• Taro Pharmaceuticals to pay more than $200 million to settle US price-fixing probe (Reuters) (DOJ)
• AstraZeneca's lung disease treatment gets FDA nod (Reuters) (Endpoints)
• Ruling threatens to upend patents on Moderna’s Covid-19 vaccine (STAT) (Endpoints)
• Another four biotechs make Wall Street debut, raising $772M+ as IPO tidal wave crests (Endpoints)
• NIH to start ‘flurry’ of large studies of potential Covid-19 treatments (STAT)
• Trump’s end run around CDC brings threat of fewer drugs for hospitals (Politico)
• Senate GOP punts coronavirus package to next week (The Hill)

• Rich country vaccine rush threatens supply security (Financial Times)
• EU eyes COVID-19 vaccines at less than $40, shuns WHO-led alliance – sources (Reuters)
• Don't expect first COVID-19 vaccinations until early 2021: WHO's Ryan (Reuters)
• WHO scientist sees regulators cooperating to speed COVID-19 vaccine approval (Reuters)
• EU prolongs duty-free import of face masks, medical gear (Reuters)
• Roche says military planes load up COVID-19 test gear as demand soars (Reuters)
• Roche cites COVID-19 and biosimilars in Q2 decline (PMLive)
• China Says It Will Have Covid-19 Vaccine Ready This Year (WSJ)
• Lonza sees no delays for COVID-19 vaccine project, citing Trump backing (Reuters)
• India sees record 49,000 new coronavirus cases, drug shortages in places (Reuters)

• A Guide to Coronavirus Vaccines in the Works (WSJ)
• New study finds hydroxychloroquine ineffective at treating COVID-19 (The Hill) (NEJM)
• Trump admin's $21M gambit for Pepcid as a COVID remedy fizzles (AP)
• Chinese COVID-19 vaccine candidate shows promise in animal tests (Reuters)
• Cipla gets India approval to sell COVID-19 drug favipiravir (Reuters)
• On eve of first big coronavirus vaccine study, trial leaders brace for 'unprecedented' task (BioPharmaDive)
• UK's home testing dogged by delays, undermining push to reduce virus transmission (Reuters)
• Novavax, Fujifilm lock up supply for late-stage COVID-19 vaccine trial (Fierce)
• RedHill Biopharma advances phase 2/3 COVID-19 programme (PMLive)
• Coronavirus (COVID-19) Update: Daily Roundup July 23, 2020 (FDA)

• Pharma deal values plummet 56% as COVID-19 disrupts resources: report (Fierce)
• Clinical trials rebound after COVID-19 crash, but can enrollment gains continue? (Science)
• EQRx, gearing up for a price war with big pharma, buys two cancer drugs (BioPharmaDive)
• BioMarin submits EU marketing application for vosoritide (PharmaTimes)
• Thermo Fisher rakes in $1.3B in coronavirus-related revenue (BioPharmaDive)
• EMA Takes A Dive Into Patient-Level Data (Pink Sheet)
• UK Pharma Exports To Fall 22% In No-Deal Brexit (Pink Sheet)
• Eli Lilly asks for a $24 million tax break for diabetes care facility expansion in Indianapolis (Pharmafile)
• As China Volume Purchase Builds, Novartis Scrambles To Launch New Products (Scrip)
• Turning cancer into a curable disease: Immunotherapy expert John Connolly picks up the reins as the new CSO of Sean Parker’s cancer institute (Endpoints)
• UCB touts another psoriasis win, this time over Cosentyx, as they look to break into packed market (Endpoints)
• Jeff Capello out the door as Michael McDonnell takes over Biogen's CFO post; Ron Bruehlman named interim CFO at IQVIA (Endpoints)
• Christoph Westphal bags a $170M Fund V, slated to help breed some new biotechs at Longwood (Endpoints)

• Abbott receives FDA approval for neurostimulator-controlling iPhone app, for personalizing therapies for pain, Parkinson's disease (Fierce)
• Edwards Lifesciences Q2 results are better than expected (MassDevice)
• AngioDynamics lands 510(k) for ‘smart’ implantable port (MassDevice)
• A test you can breathe in: Scientists are developing synthetic biosensors to monitor lung disease (STAT)
• COVID-19 diagnostics emerging as prime investment target, SVB analysis shows (MedtechDive)
• Quest says small labs ripe for acquisition as coronavirus pandemic sets stage for industry consolidation (CNBC)
• Revocation of Authorization of Emergency Use of an In Vitro Diagnostic Device for Detection and/or Diagnosis of Zika Virus (FDA)

• FDA Sends New CBD Guidance To White House Budget Office (Law360)
• Juul Quietly Revamped Its E-Cigarette, Risking the FDA’s Rebuke (Bloomberg)
• Wire-Wearing Novartis Whistle-Blower Gets $109 Million Award (Bloomberg Law)
• FBI crackdown on China’s R&D espionage intensifies with new arrests and one fugitive in San Francisco (Endpoints)